Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)
Recruiting
- Conditions
- Hepatitis Autoimmune DiseasePrimary Biliary Cholangitis (PBC)Primary Sclerosing Cholangitis (PSC)Cholestatic Genetic Diseases
- Registration Number
- NCT06767605
- Lead Sponsor
- Asociación Española para el Estudio del Hígado
- Brief Summary
The purpose of the registry is to know the status of primary biliary colgantis, autoimmune hepatitis, primary sclerosing cholagitis and genetic cholestatic diseases in Spain.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
- Patients with a confirmed diagnosis for PBC, HAI, PSC, genetic cholestatic disease
Exclusion Criteria
- Refusal to sign the informed consent for the study
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence and characteristics of autoimmune and cholestatic liver disease in Spain 2025 Evaluation of clinical characteristics of autoimmune and cholestatic liver diseases
- Secondary Outcome Measures
Name Time Method Development of liver-related events in autoimmune ahd cholestatic liver diseases 2025 Treatment of autoimmune and cholestatic liver diseases in Spain 2016-2030
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways are implicated in primary biliary cholangitis and autoimmune hepatitis in the ColHai registry?
How does obeticholic acid efficacy compare to UDCA in primary biliary cholangitis patients from the ColHai registry?
Which genetic biomarkers predict treatment response in primary sclerosing cholangitis patients enrolled in the ColHai registry?
What are the most common adverse events associated with corticosteroid therapy in autoimmune hepatitis patients in the ColHai registry?
What emerging therapies are being investigated for genetic cholestatic diseases in parallel to the ColHai registry's observational data?
Trial Locations
- Locations (1)
Hospital Clinic
🇪🇸Barcelona, Spain
Hospital Clinic🇪🇸Barcelona, SpainMaria Carlota Londoño LondoñoContactmlONDONO@clinic.cat